Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CFO Charles N. York II purchased 6,500 shares of the stock in a transaction on Friday, December 1st. The shares were purchased at an average price of $4.59 per share, with a total value of $29,835.00. Following the acquisition, the chief financial officer now owns 10,828 shares in the company, valued at approximately $49,700.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Aeglea Bio Therapeutics Inc (AGLE) traded down $0.34 during trading on Wednesday, reaching $4.74. 76,200 shares of the company’s stock traded hands, compared to its average volume of 65,901. Aeglea Bio Therapeutics Inc has a 52-week low of $2.81 and a 52-week high of $8.14.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.07. Aeglea Bio Therapeutics had a negative net margin of 527.99% and a negative return on equity of 44.05%. The firm had revenue of $1.26 million during the quarter. sell-side analysts forecast that Aeglea Bio Therapeutics Inc will post -1.97 earnings per share for the current year.

Separately, Zacks Investment Research upgraded shares of Aeglea Bio Therapeutics from a “hold” rating to a “buy” rating and set a $5.50 price target for the company in a report on Friday, November 10th.

Several hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP acquired a new stake in shares of Aeglea Bio Therapeutics during the 2nd quarter worth approximately $653,000. Vanguard Group Inc. grew its position in shares of Aeglea Bio Therapeutics by 9.4% during the 2nd quarter. Vanguard Group Inc. now owns 150,774 shares of the biotechnology company’s stock worth $579,000 after buying an additional 12,966 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of Aeglea Bio Therapeutics during the 1st quarter worth approximately $270,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Aeglea Bio Therapeutics during the 1st quarter worth approximately $157,000. 46.89% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine.

Receive News & Stock Ratings for Aeglea Bio Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics Inc and related stocks with our FREE daily email newsletter.